Drugs › Human immunoglobulin G
Brand name · Immune globulin subcutaneous, human-klhw
Xembify: adverse event reports filed with FDA
817 reports list it as a suspect or interacting product, 2020–2026. Class: Human immunoglobulin G.
- 817
- reports as suspect product
- 0% of all reports · about 126 a year
- 245
- reports, 12 months to June 2026
- 405 in the 12 months before
- 44.1%
- marked serious by the reporter
- 65.3% across the class
- 0.6%
- record death among outcomes, as reported
- 5 reports · not verified by FDA
Between January 2020 and June 2026, 817 adverse event reports received by FDA list the brand name Xembify (immune globulin subcutaneous, human-klhw) as a suspect or interacting product. Reports that mention it only as a concomitant medication (86) are left out of every figure here.
In the 12 months to June 2026, 245 reports listed it, down 40% from 405 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 126 reports a year and 0% of the 20,646,523 reports in the database, and 1.2% of the reports for the human immunoglobulin G class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded infusion site erythema (28.4%), infusion site pruritus (21.8%) and infusion site swelling (20.2%). A report can list several reactions, so shares add to more than 100%; 193 different terms appear across these reports. Infusion site erythema is recorded in 28.4% of these reports, a larger share than in the median human immunoglobulin G drug (0.8%).
44.1% of the reports are marked serious by the reporter (65.3% across the class); 0.6% record death among the outcomes and 9.1% record hospitalisation, as reported. 40.3% of the reports came from other health professionals, and the largest patient age group is 45 to 64 (25.9%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Xembify reports recording the termmedian drug in human immunoglobulin g
- Infusion site erythema28.4%232
- Infusion site pruritus21.8%178
- Infusion site swelling20.2%165
- Infusion site pain16.5%135
- Pruritusitching14.9%122
- Headachehead pain12.4%101
- Fatiguetiredness10%82
- Infusion site rash8.4%69
- Erythemaskin redness7%57
- Nauseafeeling sick7%57
- Swellingswelling6.2%51
- Painpain, site not specified5.8%47
- Infusion related reactiona reaction during or soon after an infusion5.5%45
- Rashskin rash4.8%39
- Urticariahives4.4%36
- Infusion site urticaria4.3%35
- Infusion site discolouration4.2%34
- Infusion site warmth3.3%27
- Injection site erythemaredness where the injection was given3.2%26
- Diarrhoealoose or frequent stools3.1%25
- Dizzinesslight-headedness or unsteadiness2.9%24
- Product leakage2.9%24
- Injection site painpain where the injection was given2.8%23
- Injection site pruritusitching where the injection was given2.7%22
- Infusion site nodule2.4%20
- Infusion site reaction2.4%20
- Infusion site necrosis2.3%19
- Malaisegeneral feeling of being unwell2.3%19
- Hypersensitivityan allergic-type reaction2.2%18
- Infectionan infection, type not specified2.2%18
Top 30 of 193 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 11 drugs in the human immunoglobulin g class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 70,639 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 89.5% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Immunodeficiency common variable | 175 | 21.4% |
| Primary immunodeficiency syndrome | 69 | 8.4% |
| Immunodeficiency | 60 | 7.3% |
| Hypogammaglobulinaemia | 53 | 6.5% |
| Blood immunoglobulin g decreased | 13 | 1.6% |
| Chronic inflammatory demyelinating polyradiculoneuropathy | 12 | 1.5% |
The indication field is filled in by the reporter and is often blank; shares are of all 817 reports.
In context
| Measure | Xembify | Human immunoglobulin G | All reports |
|---|---|---|---|
| Reports as suspect product | 817 | 70,639 | 20,646,523 |
| Share of that pool | — | 1.2% | 0% |
| Reports, latest 12 months | 245 | — | 1,332,454 |
| Marked serious | 44.1% | 65.3% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 6 | 74 | 91 |
| Hospitalisation recorded, per 1,000 reports | 91 | 249 | 213 |
| Consumer-filed share | 32.3% | 31.9% | 45.8% |
| Top term, share of reports | Infusion site erythema 28.4% | median 0.8% | 0% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the human immunoglobulin g class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Hizentra | brand | 22,916 | 1,422 | 45.8% |
| Human immunoglobulin g | generic | 17,139 | 2,943 | 94.5% |
| Privigen | brand | 8,718 | 579 | 69.7% |
| GAMMAGARD Liquid | brand | 8,350 | 253 | 62.7% |
| Cuvitru | brand | 4,002 | 194 | 48.7% |
| Gamunex-C | brand | 3,622 | 959 | 38.7% |
| Immune globulin | generic | 2,625 | 525 | 95.6% |
| Octagam Immune Globulin (Human) | brand | 1,121 | 85 | 78.7% |
| Immune globulin intravenous (human) | generic | 670 | 2 | 93.9% |
| Rhophylac | brand | 659 | 40 | 56.1% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Xembify reports
How many adverse event reports has FDA received for Xembify?
817 reports list Xembify as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 245 of them arrived in the latest 12 months. Another 86 list it only as a concomitant medication.
What reactions are recorded in Xembify reports?
infusion site erythema (28.4%), infusion site pruritus (21.8%), infusion site swelling (20.2%), infusion site pain (16.5%) and pruritus (14.9%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Xembify was responsible.
How serious are the reports?
44.1% are marked serious by the reporter. Among the outcomes recorded, 0.6% of reports include death and 9.1% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
other health professional (40.3%), consumer or non-health professional (32.3%) and pharmacist (17.6%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Xembify rising?
245 reports in the 12 months to June 2026, down 40% from 405 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Xembify was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Xembify?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Xembify as a suspect or interacting product; reports listing it only as a concomitant medication (86) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.